Begin Phase 2 trial of relacorilant plus enzalutamide
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Nov 2022
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer to begin next year”
What we found
Evidence strength A What the grades mean
The company's SEC filings confirm that the Phase 2 trial of relacorilant plus enzalutamide was initiated by collaborators at the University of Chicago, satisfying the commitment to begin the trial by year-end 2023.
-
A Corcept Therapeutics Inc. 10-K filed 2024-02-15
“Our collaborators at the University of Chicago have initiated a randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer, pre-prostatectomy.” ✓ confirmed on the page
Market reaction: the shares moved -6.3% against the S&P 500 over the three sessions around the disclosure (14 Feb 2024 to 20 Feb 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -92 days
- 3 versions
-
Version 1 · original · stated 3 Nov 2022
Deadline 31 Dec 2023 (“next year”)
-
Version 2 · stated 28 Feb 2023
Deadline 30 Jun 2023 (“by mid-year”) · wording expected
“Randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer expected to begin by mid-year”
-
Version 3 · stated 2 Aug 2023
Deadline 30 Sep 2023 (“third quarter”) · wording expected
“Randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer, in collaboration with the University of Chicago, expected to begin in the third quarter”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Phase 2 trial
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: in collaboration with the University of Chicago
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-CORT-002863 · Corrections policy